Key result
Prophylactic LMWH outperforms low-dose aspirin in preventing fetal loss associated with thrombogenic polymorphisms.
Why the study?
Thrombophilia in pregnancy is associated with increased risk of venous thromboembolism and placental vascular complications, but data on effective prophylaxis and treatment are limited.
Population
Pregnant women with constitutional thrombophilias
Comparison
Prophylactic low-molecular-weight heparin vs low-dose aspirin for fetal losses
Design
Review
Authors
Loading...
Thrombosis persists postpartum despite heparin prophylaxis in thrombophilia; leaves open optimal extended strategies for high-risk pregnancies.
Prophylactic low-molecular-weight heparin is more effective than low-dose aspirin for preventing fetal losses in pregnant women with constitutional thrombophilias, though data remains limited for other placental complications.
Gris et al. (2006) conducted a review in Thrombophilia in pregnancy. Prophylactic low-molecular-weight heparin vs. Low-dose aspirin was evaluated. Prophylactic low-molecular-weight heparin given from the 8th week is more efficient than low-dose aspirin for fetal losses associated with thrombogenic polymorphisms.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: